Page 126 - 2021年18期

to structure-activity relationship[J]. Toxicol In Vitro， 896.
2019，61：104642. [53] SANDEEP M S，SRIDHAR V，PUNEETH Y，et al. En-
[41] PARK J W，CHOI J S. Role of kaempferol to increase bio- hanced oral bioavailability of felodipine by naringenin in
availability and pharmacokinetics of nifedipine in rats[J]. Wistar rats and inhibition of P-glycoprotein in everted rat
Chin J Nat Med，2019，17（9）：690-697. gut sacs in vitro[J]. Drug Dev Ind Pharm，2014，40（10）：
[42] LI C，LI X，CHOI J S. Enhanced bioavailability of etopo- 1371-1377.
side after oral or intravenous administration of etoposide [54] MOTAWI T K，TELEB Z A，EL-BOGHDADY N A，et al.
with kaempferol in rats[J]. Arch Pharm Res，2009，32（1）： Effect of simvastatin and naringenin coadministration on
133-138. rat liver DNA fragmentation and cytochrome P450 activity：
[43] PIAO Y，SHIN S C，CHOI J S. Effects of oral kaempferol an in vivo and in vitro study[J]. J Physiol Biochem，2014，
on the pharmacokinetics of tamoxifen and one of its me- 70（1）：225-237.
tabolites，4-hydroxytamoxifen，after oral administration of [55] PINGILI R，VEMULAPALLI S，MULLAPUDI S S，et al.
tamoxifen to rats[J]. Biopharm Drug Dispos，2008，29（4）： Pharmacokinetic interaction study between flavanones
245-249. （hesperetin，naringenin）and rasagiline mesylate in Wistar
[44] HA H R，CHEN J，LEUENBERGER P M，et al. In vitro rats[J]. Drug Dev Ind Pharm，2016，42（7）：1110-1117.
inhibition of midazolam and quinidine metabolism by fla- [56] ZHANG F Y，DU G J，ZHANG L，et al. Naringenin en-
vonoids[J]. Eur J Clin Pharmacol，1995，48（5）：367-371. hances the anti-tumor effect of doxorubicin through selec-
[45] PATEL J，BUDDHA B，DEY S，et al. In vitro interaction tively inhibiting the activity of multidrug resistance-asso-
of the HIV protease inhibitor ritonavir with herbal consti- ciated proteins but not P-glycoprotein[J]. Pharm Res，
tuents：changes in P-gp and CYP3A4 activity[J]. Am J 2009，26（4）：914-925.
Ther，2004，11（4）：262-277. [57] QIU J X，ZHOU Z W，HE Z X，et al. Estimation of the
[46] LIMTRAKUL P，KHANTAMAT O，PINTHA K. Inhibi- binding modes with important human cytochrome P450 en-
tion of P-glycoprotein function and expression by kaemp- zymes，drug interaction potential，pharmacokinetics，and
ferol and quercetin[J]. J Chemother，2005，17（1）：86-95. hepatotoxicity of ginger components using molecular
[47] IMAI Y，TSUKAHARA S，ASADA S，et al. Phytoestro- docking，computational，and pharmacokinetic modeling
gens/flavonoids reverse breast cancer resistance protein/ studies[J]. Drug Des Devel Ther，2015，9：841-866.
ABCG2-mediated multidrug resistance[J]. Cancer Res， [58] MA Y L，ZHAO F，YIN J T，et al. Two approaches for
2004，64（12）：4346-4352. evaluating the effects of galangin on the activities and
[48] MANDERY K，BUJOK K，SCHMIDT I，et al. Influence mRNA expression of seven CYP450[J]. Molecules，2019，24
of the flavonoids apigenin，kaempferol，and quercetin on （6）：1171.
the function of organic anion transporting polypeptides [59] LOU D，BAO S S，LI Y H，et al. Inhibitory mechanisms of
1A2 and 2B1[J]. Biochem Pharmacol，2010，80（11）： myricetin on human and rat liver cytochrome P450 en-
1746-1753. zymes[J]. Eur J Drug Metab Pharmacokinet，2019，44（5）：
[49] FAN X，BAI J，HU M，et al. Drug interaction study of fla- 611-618.
vonoids toward OATP1B1 and their 3D structure activity [60] LI Y，NING J，WANG Y，et al. Drug interaction study of
relationship analysis for predicting hepatoprotective effects flavonoids toward CYP3A4 and their quantitative struc-
[J]. Toxicology，2020，437：152445. ture activity relationship（QSAR）analysis for predicting
[50] QUINTIERI L，PALATINI P，NASSI A，et al. Flavonoids potential effects[J]. Toxicol Lett，2018，294：27-36.
diosmetin and luteolin inhibit midazolam metabolism by [61] WEI Y，ZHOU S，HAO T，et al. Further enhanced dissolu-
human liver microsomes and recombinant CYP3A4 and tion and oral bioavailability of docetaxel by coamorphiza-
CYP3A5 enzymes[J]. Biochem Pharmacol，2008，75（6）： tion with a natural P-gp inhibitor myricetin[J]. Eur J
1426-1437. Pharm Sci，2019，129：21-30.
[51] AN G，WANG X，MORRIS M E. Flavonoids are inhibi- [62] CHOI S J，SHIN S C，CHOI J S. Effects of myricetin on
tors of human organic anion transporter 1（OAT1）-media- the bioavailability of doxorubicin for oral drug delivery in
ted transport[J]. Drug Metab Dispos，2014，42（9）：1357- rats：possible role of CYP3A4 and P-glycoprotein inhibi-
1366. tion by myricetin[J]. Arch Pharm Res，2011，34（2）：309-
[52] LU W J，FERLITO V，XU C，et al. Enantiomers of narin- 315.
genin as pleiotropic，stereoselective inhibitors of cyto- [63] ZANDEN J V，MUL A D，WORTELBOER H M，et al. Re-
chrome P450 isoforms[J]. Chirality，2011，23（10）：891- versal of in vitro cellular MRP1 and MRP2 mediated vin-

·2292 · China Pharmacy 2021 Vol. 32 No. 18 中国药房 2021年第32卷第18期